EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Matching‐adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis

Jan Astermark iD, Tyler W Buckner, Laurent Frenzel iD, Anthony J Hatswell, Xiaojun You, Hai Liu, Erin Goodman, Sandra Santos, Charles Hawes, David Hinds, Robert Klamroth iD

Haemophilia · 2023

DOI: 10.1111/hae.14818 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Haemophilia, 2023. Verfasst von Jan Astermark und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Medicine, Lund University, Lund, Sweden. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Hemophilia A. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: BioMarin Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Head‐to‐head evaluation of valoctocogene roxaparvovec, the first gene therapy approved for haemophilia A, with emicizumab is not available. Therefore, phase 3 trial data were indirectly compared.

Aim

To compare bleeding rates in trials evaluating 6 × 10 13 vg/kg valoctocogene roxaparvovec (GENEr8‐1; NCT03370913), 1.5 mg/kg emicizumab dosed every week (HAVEN 3; NCT02847637), and FVIII prophylaxis (270–902) in participants with severe haemophilia A (FVIII ≤1 IU/dL).

Methods

Valoctocogene roxaparvovec versus emicizumab and FVIII prophylaxis as used in 270–902 versus emicizumab cross‐trial comparisons were performed using matching‐adjusted indirect comparison (MAIC). Individual participant data from GENEr8‐1 and 270–902 were weighted to equalise aggregate participant baseline characteristics from HAVEN 3. After MAIC weighting, annualised bleeding rates (ABR) and proportions of participants without bleeds were compared for treated bleeds, all bleeds, treated joint bleeds, and treated spontaneous bleeds.

Results

After MAIC weighting, ABR for all bleeds was statistically significantly lower with valoctocogene roxaparvovec than emicizumab (rate ratio [95% CI], .55 [.33–.93]). Additionally, significantly higher proportions of participants had no treated joint bleeds (odds ratio [95% CI], 2.75 [1.20–6.31]) and no treated bleeds (3.25 [1.53–6.90]) with valoctocogene roxaparvovec versus emicizumab. When compared with the mainly standard half‐life FVIII prophylaxis regimens in 270–902, mean ABRs (except for all bleeds) were significantly lower, and significantly higher proportions reported 0 bleeds for all outcomes with emicizumab.

Conclusion

Valoctocogene roxaparvovec provided generally lower bleeding rates and higher probability of no bleeds, including treated joint bleeds, than emicizumab. Emicizumab was more effective than FVIII prophylaxis regimens used in 270–902.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificHemophilia AHumansFactor VIIIGenetic TherapyHemarthrosisHemorrhageAntibodies, Monoclonal, HumanizedRecombinant Fusion ProteinsGene Therapy Agents

Stichwörter der Autor:innen

AAV5-hFVIII-SQFVIII prophylaxisemicizumabhaemophilia Amatching-adjusted indirect comparison (MAIC)valoctocogene roxaparvovec

Substanzen

Antibodies, BispecificFactor VIIIemicizumabAntibodies, Monoclonal, HumanizedValoctocogene RoxaparvovecRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Department of Translational Medicine, Lund University, Lund, Sweden.
  • Department for Hematology, Oncology and Radiation Physics, Skåne University Hospital, Malmö, Sweden.
  • University of Colorado School of Medicine Hemophilia and Thrombosis Center, Aurora, Colorado, USA.
  • Centre de Traitement de l'Hemophilie, AP-HP, Hôpital Universitaire Necker-Enfants Malades, Paris, France.
  • Delta Hat Limited, Nottingham, UK.
  • Department of Statistics, University College London, London, UK.

ORCID-Profile: Jan Astermark, Laurent Frenzel, Robert Klamroth

Förderung

  • BioMarin Pharmaceutical

Zitieren

APA

Astermark, J., Buckner, T. W., Frenzel, L., Hatswell, A. J., You, X., Liu, H., Goodman, E., Santos, S., Hawes, C., Hinds, D., & Klamroth, R. (2023). Matching‐adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis. Haemophilia. https://doi.org/10.1111/hae.14818

Vancouver

Astermark J, Buckner TW, Frenzel L, Hatswell AJ, You X, Liu H, et al. Matching‐adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis. Haemophilia. 2023. doi:10.1111/hae.14818

BibTeX
@article{Astermark2023,
  author = {Astermark, Jan and Buckner, Tyler W and Frenzel, Laurent and Hatswell, Anthony J and You, Xiaojun and Liu, Hai and Goodman, Erin and Santos, Sandra and Hawes, Charles and Hinds, David and Klamroth, Robert},
  title = {Matching‐adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis},
  journal = {Haemophilia},
  year = {2023},
  doi = {10.1111/hae.14818}
}
Kostenlos starten →